DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
-
GYKI 52466 hydrochloride (HB0311)
Description:Selective, non-competitive AMPA receptor antagonist
Purity:>98%
-
GYKI 53655 hydrochloride (HB0312)
Description:Non-competitive AMPA receptor antagonist. Also blocks kainate GluK3 homomeric receptors.
Purity:>98%
-
H 89 dihydrochloride (HB0314)
Description:Potent, non-selective kinase inhibitor.Also improves dissociate hESCs survival and clonogenicity.
Purity:>99%
-
HA 1100 hydrochloride (HB2293)
Description:Selective, reversible, cell-permeable ROCK inhibitor
Purity:>99%
-
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
